Airway disease: similarities and differences between asthma, COPD and bronchiectasis

Athanazio, Rodrigo Abensur

doi:10.6061/clinics/2012(11)19

Cited by 88 publications

(67 citation statements)

References 112 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Yet the inclusion in this group of users both patients with asthma and those with COPD with some reversible obstructive component presents a limitation. In Denmark, the number of prescriptions for inhalated bronchodilating agents for indications other than asthma or ROPD remains low, but the possibility exists that a small portion of patients using inhalated bronchodilating agents have COPD without a reversible component, 25,27,28 which may confound our conclusion. Consequently, a subgroup analysis of patients with or without a diagnosis of asthma showed an increase in the relative risk of rupture to about twice as high a risk of rupture.…”

Section: Discussionmentioning

confidence: 88%

Asthma Associates With Human Abdominal Aortic Aneurysm and Rupture

Liu

Wemmelund

Wang

et al. 2016

ATVB

View full text Add to dashboard Cite

Objective Asthma and abdominal aortic aneurysms (AAA) both involve inflammation. It remains unknown whether these diseases interact. Approach and Results Databases analyzed included DNRP: a population-based nationwide case-control study included all patients with ruptured AAA (rAAA) and age- and sex-matched AAA controls without rupture in Denmark from 1996–2012. VIVA: Subgroup study of participants from the population-based randomized Viborg vascular screening trial. Asthmatic patients were categorized by hospital diagnosis, bronchodilator use, and the recorded use of other anti-asthma prescription medications. Logistic regression models were fitted to determine whether asthma associated with the risk of rAAA in DNRP, and an independent risk of having an AAA at screening in the VIVA trial. From the DNRP study, asthma diagnosed less than one year or six months before the index date increased the risk of AAA rupture before (odds ratio OR=1.60, 2.12) and after (OR=1.51, 2.06) adjusting for AAA comorbidities. Use of bronchodilators elevated the risk of AAA rupture from ever use to within 90 days from the index date, before (OR=1.10~1.37) and after (OR=1.10~1.31) adjustment. Patients prescribed anti-asthma drugs also showed an increased risk of rupture before (OR=1.12~1.79) and after (OR=1.09~1.48) the same adjustment. In VIVA, anti-asthmatic medication use associated with increased risk of AAA before (OR=1.45) or after adjustment for smoking (OR=1.45) or other risk factors (OR=1.46). Conclusions Recent active asthma increased risk of AAA and AAA-rupture. These findings document and furnish novel links between airway disease and AAA, two common diseases that share inflammatory aspects.

show abstract

Section: Discussionmentioning

confidence: 88%

Asthma Associates With Human Abdominal Aortic Aneurysm and Rupture

Liu

Wemmelund

Wang

et al. 2016

ATVB

View full text Add to dashboard Cite

show abstract

“…These observations are not only relevant to CF but also to other airway diseases associated with inflammation, defective wound response and lung tissue remodelling, including asthma, chronic obstructive pulmonary disease (COPD) and bronchiectasis. 62,63…”

Section: Ehf Promotes Expression Of Sam Pointed-domain Containing Etsmentioning

confidence: 99%

Coordinate regulation of ELF5 and EHF at the chr11p13 CF modifier region

Swahn

Ebron

Lamar

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

E74‐like factor 5 (ELF5) and ETS‐homologous factor (EHF) are epithelial selective ETS family transcription factors (TFs) encoded by genes at chr11p13, a region associated with cystic fibrosis (CF) lung disease severity. EHF controls many key processes in lung epithelial function so its regulatory mechanisms are important. Using CRISPR/Cas9 technology, we removed three key cis‐regulatory elements (CREs) from the chr11p13 region and also activated multiple open chromatin sites with CRISPRa in airway epithelial cells. Deletion of the CREs caused subtle changes in chromatin architecture and site‐specific increases in EHF and ELF5. CRISPRa had most effect on ELF5 transcription. ELF5 levels are low in airway cells but higher in LNCaP (prostate) and T47D (breast) cancer cells. ATAC‐seq in these lines revealed novel peaks of open chromatin at the 5’ end of chr11p13 associated with an expressed ELF5 gene. Furthermore, 4C‐seq assays identified direct interactions between the active ELF5 promoter and sites within the EHF locus, suggesting coordinate regulation between these TFs. ChIP‐seq for ELF5 in T47D cells revealed ELF5 occupancy within EHF introns 1 and 6, and siRNA‐mediated depletion of ELF5 enhanced EHF expression. These results define a new role for ELF5 in lung epithelial biology.

show abstract

“…La inflamación de las vías aéreas constituye un rasgo común para la EPOC y otras enfermedades obstructivas de gran prevalencia, como el asma o la bronquiectasia. Sin embargo, el patrón inflamatorio de estas enfermedades presenta diferentes características 10,11 . En el asma, los eosinófilos, los mastocitos y los linfocitos T CD4 + representan las células inflamatorias protagonistas del proceso inflamatorio.…”

Section: Efectores Celulares Inflamatorios En La Epocunclassified

Efectores celulares de la respuesta inflamatoria en la enfermedad pulmonar obstructiva crónica

Montés

García‐Valero³

et al. 2015

Rev. méd. Chile

View full text Add to dashboard Cite

Approximately 3 million people in the world die every year as a consequence of COPD, which is associated with an abnormal inflammatory response of the lung to noxious particles and gases. This inflammatory pattern causes pathological changes leading to a narrowing of small airways and destruction of lungjordiog82@gmail.com L a enfermedad pulmonar obstructiva crónica (EPOC) es un proceso patológico de alta prevalencia, considerado en la actualidad la cuarta causa de muerte en el mundo y que, se estima, se convertirá en la tercera en el año 2030 1 . En los países de América Latina, 35 de cada 1.000 hospitalizaciones se deben a la EPOC, con un alto coste económico y con rangos de mortalidad intrahospitalaria que van de 6,7% a 29,5% 2 . En Chile, las enfermedades respiratorias constituyen la tercera causa de muerte y, entre ellas, la EPOC ocupa el segundo lugar, representando a 22% de los decesos 3 . Por su parte, el Proyecto Latinoamericano de Investigación en Obstrucción Pulmonar (PLATINO) ha reportado que la prevalencia de la EPOC en Santiago de Chile es de 6,3% en la población mayor de 40 años 4 . La EPOC se define como una enfermedad caracterizada por una limitación al flujo aéreo no completamente reversible, progresiva y que se asocia a una respuesta inflamatoria anormal de los pulmones a partículas nocivas o gases 5 . Esta enfermedad comprende tanto los síntomas clínicos de la bronquitis/bronquiolitis crónica como los de la patología derivada del enfisema pulmonar. La confirmación diagnóstica se obtiene al realizar pruebas espirométricas, las cuales permiten determinar la obstrucción del flujo aéreo y el grado de alteración de la función pulmonar a partir del volumen espirado forzado en el primer segundo (VEF 1 ), la capacidad vital forzada (CVF) y la relación de estos dos parámetros clínicos (VEF 1 /CVF) 5 . Se considera al humo del tabaco como el prin-

show abstract

Airway disease: similarities and differences between asthma, COPD and bronchiectasis

Cited by 88 publications

References 112 publications

Asthma Associates With Human Abdominal Aortic Aneurysm and Rupture

Asthma Associates With Human Abdominal Aortic Aneurysm and Rupture

Coordinate regulation of ELF5 and EHF at the chr11p13 CF modifier region

Efectores celulares de la respuesta inflamatoria en la enfermedad pulmonar obstructiva crónica

Contact Info

Product

Resources

About